Mirtazapine in treating the fibromyalgia without concomitant depression
Researchers have found that there is a correlation between fibromyalgia and depression. The stress caused from fibromyalgia's constant pain and fatigue results in anxiety and social isolation. The chronic deep muscle and trigger point pain also results into reduced activity and leads to depression. Depression and fibromyalgia can greatly interfere with the daily activities.
This can be cured by the administration of medications and their combinations. Physicians suggested that drugs like mirtazapine is effective in reducing the pain or symptoms of fibromyalgia without concomitant depression.
Thus, to evaluate the efficacy and safety of mirtazapine in Japanese patients with fibromyalgia, a randomized study was conducted. In a parallel-group, randomized, double-blind, placebo-controlled phase II a study, patients of age group between 20-64 years were selected. Patients who met the American College of Rheumatology 1990 diagnostic fibromyalgia criteria and had stably high pain scores during a placebo run in period were selected. Mirtazapine was given to patients orally for 12 weeks.
Of the 430 patients, 422 were analyzed for the primary end point. After analysis, mirtazapine caused a significantly greater reduction in the mean numerical rating pain score as compared to placebo. Even other patients, who were treated with mirtazapine had reduced pain score with improved quality of life which was assessed by Japanese version of the Fibromyalgia Impact Questionnaire and Short-Form 36 Questionnaire. Common adverse events observed included weight gain, somnolence and increased appetite. But still, mirtazapine has proven to be an effective and safe treatment for Japanese patients with fibromyalgia without concomitant depression.